LungLife AI, Inc.
LungLife AI, Inc. (LLAI.L) Stock Overview
Explore LungLife AI, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
1.3M
P/E Ratio
-0.36
EPS (TTM)
$-0.12
ROE
-0.56%
LLAI.L Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of LungLife AI, Inc. (LLAI.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 74.55, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $5.68.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.36 and a market capitalization of 1.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
LungLife AI, Inc., a cancer diagnostics company, develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology. It engages in developing LungLB, an AI enhanced, blood-based test to utilize machine learning to identify and count CTCs with reducing operator hands-on time and increasing test performance. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. The company is based in Thousand Oaks, California.
Paul Pagano
8
2545 West Hillcrest Drive, Thousand Oaks, CA
2021